COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF

PURPOSE: In 2018,Optune (TTF) became available covered by public insurance for patients with glioblastoma,based on the effectiveness of the US EF-14 study (TTF + TMZ (temozolomide) vs. TMZ). There are problems such as use of at least 18 hours a day,behavior restrictions,expensive medical expenses,et...

Descripción completa

Detalles Bibliográficos
Autores principales: Omura, Takaki, Miyakita, Yasuji, Ohno, Makoto, Takahashi, Masamichi, Satomi, Natsuko, Fujimoto, Kenji, Omura, Tomoko, Narita, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213445/
http://dx.doi.org/10.1093/noajnl/vdz039.203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213445/
http://dx.doi.org/10.1093/noajnl/vdz039.203

Ejemplares similares